XPhyto Therapeutics Corp (CSE:XPHY) (OTCMKTS:XPHYF) said Monday that the development of epilepsy treatment products using its proprietary oral thin film delivery system will be a “priority” initiative for 2020.
The science-focused cannabis company said in a statement that it is focusing on generic cannabidiol-based dissolvable oral wafers for the treatment of severe childhood forms of epilepsy, specifically Dravet syndrome and Lennox-Gastaut syndrome.
Challenging to diagnose and treat, patients suffering these two forms of severe epilepsy often develop severe neurologic, intellectual, and behavioral disorders that progressively worsen.
Current FDA/EMA-approved CBD-based treatment for Dravet and Lennox-Gastaut is founded on a plant extract oil containing 100 mg of CBD per millilitre. Based on initial dissolution testing using XPhyto's proprietary thin film drug delivery system, previously announced on November 11, the company's oral delivery system may yield as much as a "10 to 20x increase in bioavailability of CBD" over existing oil delivery methods, said the company.
"XPhyto believes that an efficient and well-defined dosage form is the future of cannabis-based medicine. High bioavailability with controlled and reproducible delivery is critical," said XPhyto Therapeutics CEO Hugh Rogers in a statement.
"Our initial results suggest significant potential timing and efficiency advantages over conventional delivery methods," he added.
XPhyto's thin film drug delivery system was developed by its wholly-owned German subsidiary, Vektor Pharma TF GmbH. Vektor is a narcotics manufacturer, importer, and researcher located near Munich, Germany.
Vektor's previous development work has included narcotics delivery systems for conventional oncology and non-oncology pain treatment, such as Fentanyl, Hydromorphone, and Oxycodone, and more recently, the development of efficient cannabis delivery and dosage systems.
Oral thin film drug delivery is a large and hyper-growth international industry which provides an alternative to conventional solid and liquid oral dosage forms. The global market for thin film drug manufacturing will be worth $15.984 billion by 2024, and is estimated to expand at a solid 9% compound annual growth rate between 2019 and 2024, according to Transparency Market Research
XPhyto Therapeutics is a science-focused cannabis company developing analytical testing, processing, and formulation capability in Canada. In addition to subsidiary Vektor Pharma TF GmbH, XPhyto has also acquired 100% ownership of the German cannabis company Bunker Pflanzenextrakte GmbH. The company operates from a decommissioned German Air Force command center and nuclear bunker near Munich, hence its name, which is the largest cannabis laboratory in Germany.
Contact the author Uttara Choudhury at firstname.lastname@example.org
Follow her on Twitter: @UttaraProactive